DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quibron-T (Theophylline, Anhydrous) - Summary

 
 



QUIBRON-T SUMMARY

QUIBRON®-T
(Theophylline Tablets USP)
ACCUDOSE® Tablets
IMMEDIATE-RELEASE BRONCHODILATOR

Theophylline is structurally classified as a methylxanthine.

Quibron-T is available as tablets intended for oral administration, containing 300 mg of anhydrous theophylline per tablet. Quibron-T is an oral bronchodilator in an immediate-release formulation in the ACCUDOSE Tablet design. With functional trisects and bisects, Quibron-T Tablets can be accurately divided into 100-, 150-, and 200-mg segments to provide a variety of dosing increments, as required.

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.


See all Quibron-T indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Quibron-T (Theophylline)

Discovery of Asthma Subtypes Suggests New Therapies
Source: Medscape Allergy & Clinical Immunology Headlines [2015.08.26]
Some patients with severe asthma do not respond to new biologic therapies in development, and now researchers might have discovered the reason, as well as what kinds of therapies might work instead.
Medscape Medical News

How a throw-away paper cup can save the life of a child with asthma
Source: Respiratory / Asthma News From Medical News Today [2015.08.21]
A disposable cup - favoured by many of the high street's well known coffee shops - is the inspiration behind a new and scientifically reviewed device for the safe and prompt treatment of school age...

Study reveals new insights into how asthma 'pathways' could be blocked
Source: Respiratory / Asthma News From Medical News Today [2015.08.20]
University of Leicester researchers involved in study demonstrating how combining novel treatments currently in development may lead to better asthma controlResearchers from the University of...

Asthma Myths Pictures Slideshow
Source: MedicineNet Asthma Complexities Specialty [2015.08.19]
Title: Asthma Myths Pictures Slideshow
Category: Slideshows
Created: 12/15/2008 12:00:00 AM
Last Editorial Review: 8/19/2015 12:00:00 AM

Exploring 'clinical conundrum' of asthma-COPD overlap in nonsmokers with chronic asthma
Source: Respiratory / Asthma News From Medical News Today [2015.08.06]
Researchers may be closer to finding the mechanism responsible for loss of lung elastic recoil and airflow limitation in nonsmokers with chronic asthma.

more news >>

Published Studies Related to Quibron-T (Theophylline)

Beneficial effects of theophylline infusions in surgical patients with intra-abdominal hypertension. [2011.08]
BACKGROUND: Intra-abdominal hypertension (IAH) can cause high mortality. Recently, we found that IAH was associated with increased serum levels of adenosine and interleukin 10. Our present "hypothesis-generated study" was based on the above mentioned results... CONCLUSIONS: Adenosine receptor antagonism with T following IAH diagnosis resulted in markedly reduced mortality in patients with moderated IAH (<20 mmHg). Theophylline-associated mortality reduction may be related to improved renal perfusion and improved MAP, presumably caused by adenosine receptor blockade. Because this study was not a randomized controlled study, these compelling observations require further multicentric clinical confirmation.

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. [2011.07]
OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2... CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.11]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.09.29]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Adenosine receptor inhibition with theophylline attenuates the skin blood flow response to local heating in humans. [2010.09]
Mechanisms underlying the robust cutaneous vasodilatation in response to local heating of human skin remain unresolved. Adenosine receptor activation has been shown to induce vasodilatation via nitric oxide, and a substantial portion of the plateau phase to local heating of human skin has been shown to be dependent on nitric oxide...

more studies >>

Clinical Trials Related to Quibron-T (Theophylline)

The Effect of Theophylline in the Treatment of Bronchiectasis [Completed]
Theophylline was well recommended in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. However, there is no supporting evidence for their efficacy in the treatment of bronchiectasis. Our hypothesis is that theophylline will play a role in bronchiectasis. Our purpose is to examine the efficacy and safety of 24 weeks treatment with theophylline in subjects with non-cystic fibrosis bronchiectasis.

Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study [Recruiting]
The aim of this multi-centre, double blind, randomised, controlled trial (DBRCT) is to assess the effect of low dose theophylline, singly and in combination with low dose oral prednisone, on COPD (Chronic Obstructive Pulmonary Disease) exacerbations, quality of life and secondary clinical outcomes compared with usual therapy and placebo over 48 weeks of treatment. Approximately 2400 symptomatic patients with COPD will be recruited in China for comparison of low dose theophylline versus placebo and low dose theophylline + low dose prednisone The primary end-point for this study is the difference between the three treatment groups in

- COPD exacerbation rate

- Time to first severe exacerbation requiring hospitalisation or death

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis [Completed]
The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.

Drug Interaction Study of Colchicine and Theophylline [Completed]
Colchicine is a supressor of hepatic CYP1A2 and theophylline is a sensitive CYP1A2 probe substrate. When the two are co-administered the potential exists for a clinically significant drug interaction. This study aims to determine the effect of steady-state colchicine on the pharmacokinetics of theophylline administered as a single dose. A secondary goal is to evaluate the safety and tolerability of this regimen in healthy volunteers. All study subjects will be monitored for adverse events throughout the entire study period.

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline [Recruiting]
This study is to determine the use of theophylline in patients with NSCLC and advanced solid malignancies and whether treatment with theophylline will help lower or diminish the side effect of diarrhea in patients taking erlotinib. Patients will be enrolled in one of two parts of the study to verify the lowest dose of theophylline that is effective and the highest dose of erlotinib that can be tolerated with theophylline. If this study shows that theophylline is able to inhibit erlotinib induced diarrhea, it will help demonstrate that patients using the tyrosine kinase inhibitor (TKIs), erlotinib, can use it effectively at higher doses without experiencing severe diarrhea.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Quibron-T has an overall score of 5. The effectiveness score is 4 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Quibron-T review by 52 year old female patient

  Rating
Overall rating:  
Effectiveness:   Marginally Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   asthma
Dosage & duration:   300 mg 2x day taken daily for the period of about 10 years
Other conditions:   migraines, depression
Other drugs taken:   birth control, proventil inhaler
  
Reported Results
Benefits:   the medication kept my asthma under control or so i thought. as an aside, i still have a few left and every so often if i am out of my migraine medication, i will take a theodur and it seems to alleviate the headache. it was inexpensive.
Side effects:   while I was on it, i never really experienced any side effects. except one time when i accidently took too much and became dizzy and nauseaus. when i went off it i suffered two weeks of migraines due to withdrawal.
Comments:   i took 300 mg. twice a day and also used an inhaler regularly. i assumed it was as good as it gets. my new asthma specialist determined i had suffered some loss of lung function as the asthma had not been controlled as well as it could have been. i had to have regular blood work to determine the levels were right.

See all Quibron-T reviews / ratings >>

Page last updated: 2015-08-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015